All In Biotech

Drug Trial Radar · NCT01336634

Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.

A Phase II Study of the BRAF Inhibitor Dabrafenib as a Single Agent and in Combination With the MEK Inhibitor Trametinib in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer

Last checked: Nov 20, 2026Latest source record: Apr 4, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

177

Actual

Start

Aug 5, 2011

Primary completion

Oct 1, 2015

Study completion Jan 7, 2021

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Apr 18, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a Phase II, multicenter, non-randomized, open-label study to assess the efficacy, safety, and tolerability of dabrafenib administered as a single agent and in combination with trametinib in stage IV disease to subjects with BRAF mutant advanced non-small cell lung cancer. Central confirmation testing for the BRAF V600E mutation was performed and a sufficient number of subjects were enrolled with the intent of having at least 125 centrally confirmed subjects among the three cohorts.

Conditions

  • Cancer

Interventions

  • DabrafenibDrug

    Dabrafenib study treatment was provided as 50 mg and 75 mg hydroxypropyl methylcellulose (HPMC) capsules. Each capsule contains 50 mg or 75 mg of free base (present as the mesylate salt)

  • TrametinibDrug

    Trametinib study treatment was provided as 0.5 mg and 2 mg tablets. Each tablet contained 0.5 mg or 2 mg of trametinib parent (present as the dimethyl sulfoxide solvate)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Rate (ORR)Time frame: From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months

Locations

50 sites in 11 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Los Angeles, California

  • Novartis Investigative Site

    Orange, California

  • Novartis Investigative Site

    Aurora, Colorado

  • Novartis Investigative Site

    Tampa, Florida

  • Novartis Investigative Site

    Baltimore, Maryland

  • Novartis Investigative Site

    Boston, Massachusetts

  • Novartis Investigative Site

    Boston, Massachusetts

  • Novartis Investigative Site

    Ann Arbor, Michigan

  • Novartis Investigative Site

    St Louis, Missouri

  • Novartis Investigative Site

    Lebanon, New Hampshire

  • Novartis Investigative Site

    New York, New York

  • Novartis Investigative Site

    Columbus, Ohio

  • Novartis Investigative Site

    Pittsburgh, Pennsylvania

  • Novartis Investigative Site

    Seattle, Washington

  • Novartis Investigative Site

    Madison, Wisconsin

  • Novartis Investigative Site

    Caen, France

  • Novartis Investigative Site

    Lille, France

  • Novartis Investigative Site

    Marseille, France

  • Novartis Investigative Site

    Pierre-Bénite, France

  • Novartis Investigative Site

    Saint-Herblain, France

  • Novartis Investigative Site

    Strasbourg, France

  • Novartis Investigative Site

    Toulouse, France

  • Novartis Investigative Site

    Villejuif, France

  • Novartis Investigative Site

    Frankfurt am Main, Germany

  • Novartis Investigative Site

    Großhansdorf, Germany

  • Novartis Investigative Site

    Heidelberg, Germany

  • Novartis Investigative Site

    Moers, Germany

  • Novartis Investigative Site

    Milan, Italy

  • Novartis Investigative Site

    Milan, Italy

  • Novartis Investigative Site

    Orbassano, Italy

  • Novartis Investigative Site

    Osaka, Japan

  • Novartis Investigative Site

    Tokyo, Japan

  • Novartis Investigative Site

    Amsterdam, Netherlands

  • Novartis Investigative Site

    Groningen, Netherlands

  • Novartis Investigative Site

    Oslo, Norway

  • Novartis Investigative Site

    Seoul, South Korea

  • Novartis Investigative Site

    Seoul, South Korea

  • Novartis Investigative Site

    Seoul, South Korea

  • Novartis Investigative Site

    Barcelona, Spain

  • Novartis Investigative Site

    Barcelona, Spain

Showing 40 of 50 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.